.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Colorcon
AstraZeneca
McKesson
Queensland Health
Federal Trade Commission
Healthtrust
Johnson and Johnson
Cipla

Generated: December 17, 2017

DrugPatentWatch Database Preview

Janssen Prods Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PRODS, and when can generic versions of JANSSEN PRODS drugs launch?

JANSSEN PRODS has six approved drugs.

There are twenty-five US patents protecting JANSSEN PRODS drugs.

There are five hundred and twenty patent family members on JANSSEN PRODS drugs in forty-nine countries and one hundred and ten supplementary protection certificates in thirteen countries.

Summary for Janssen Prods

International Patents:520
US Patents:25
Tradenames:5
Ingredients:5
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-004Dec 18, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-004Dec 18, 2008RXYesNo► Subscribe► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-002Feb 25, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-006Nov 9, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-004Dec 18, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-002Feb 25, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-003Oct 21, 2008DISCNYesNo► Subscribe► SubscribeY► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-002Feb 25, 2008RXYesNo► Subscribe► Subscribe► Subscribe
Janssen ProdsPREZCOBIXcobicistat; darunavir ethanolateTABLET;ORAL205395-001Jan 29, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen ProdsEDURANTrilpivirine hydrochlorideTABLET;ORAL202022-001May 20, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Janssen Prods

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-002Feb 25, 2008► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-005Dec 18, 2008► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateSUSPENSION;ORAL202895-001Dec 16, 2011► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-003Oct 21, 2008► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-003Oct 21, 2008► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-001Jun 23, 2006► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-006Nov 9, 2012► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-003Oct 21, 2008► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-004Dec 18, 2008► Subscribe► Subscribe
Janssen ProdsPREZISTAdarunavir ethanolateTABLET;ORAL021976-003Oct 21, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JANSSEN PRODS drugs

Drugname Dosage Strength Tradename Submissiondate
darunavir ethanolateTablets800 mgPREZISTA5/14/2013

Non-Orange Book Patents for Janssen Prods

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,139,541Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,383,655Modulators of pharmacokinetic properties of therapeutics► Subscribe
7,608,590HCV NS-3 serine protease inhibitors► Subscribe
8,067,449Modulators of pharmacokinetic properties of therapeutics► Subscribe
7,956,063Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile► Subscribe
8,486,942Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,153,800Macrocyclic inhibitors of hepatitis C virus► Subscribe
9,580,392HIV replication inhibiting pyrimidines► Subscribe
8,088,770Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,841,310Combinations of a pyrimidine containing NNRTI with RT inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen Prods Drugs

Country Document Number Estimated Expiration
Ukraine78221► Subscribe
Denmark1658848► Subscribe
Taiwan200909422► Subscribe
Japan6147282► Subscribe
CroatiaP20100048► Subscribe
Ukraine97112► Subscribe
HungaryS1600060► Subscribe
Eurasian Patent Organization200900155► Subscribe
New Zealand553322► Subscribe
World Intellectual Property Organization (WIPO)9701349► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Janssen Prods Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00003Denmark► SubscribePRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG ATAZANAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER ATAZANAVIRSULFAT; REG. NO/DATE: EU/1/15/1025/001-002 20150715
864Luxembourg► SubscribePRODUCT NAME: COBICISTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; FIRST REGISTRATION DATE: 20130527
0150040 00167Estonia► SubscribePRODUCT NAME: RILPIVIRIINI (VESINIKKLORIIDSOOLANA), TENOFOVIIR-;REG NO/DATE: EU/1/11/737/001-002 28.11.2011
2015000088Germany► SubscribePRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
/2016Austria► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715
C0035France► SubscribePRODUCT NAME: RILPIVIRINE AINSI QUE SES FORMES THERAPEUTIQUEMENT PROTEGEES PAR LE BREVET DE BASE, TELLES QUE LES SELS D'ADDITION DE RILPIVIRINE PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
2016000108Germany► SubscribePRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, Z.B. EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621
2016039Lithuania► SubscribePRODUCT NAME: ATAZANAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713
0860Netherlands► SubscribePRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN TENOFOVIR-ALAFENAMIDE, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIR-ALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1061 20151123
2015037Lithuania► SubscribePRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM + EMTRICITABINUM; REGISTRATION NO/DATE: EU/1/11/737/001 2011 11 28, EU/1/11/737/002 20111128
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Harvard Business School
US Army
Cantor Fitzgerald
Citi
Medtronic
McKinsey
AstraZeneca
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot